CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 enrolled
Drug / intervention
Resveratrol, Quercetin, Curcumin (RQC) +1 moredrug
Likely dose
Resveratrol, Quercetin, Curcumin (RQC) 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05062486
NCT05062486Phase 2Completed
CompareCT.gov

An Open-Label, Randomized, Double Arm, Phase 2 Study to Evaluate the Safety and Efficacy of C and RQC for Preventing Progression in Age-Related Macular Degeneration

Paul A Knepper, MD PhD·interventional·Posted Sep 30, 2021·Updated Jul 30, 2025

In Brief

A Phase 2 clinical trial evaluating Resveratrol, Quercetin, Curcumin (RQC) and Curcumin for Age-related Macular Degeneration. Completed, enrolled 55 participants across 1 site.

Detailed Summary

To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration (AMD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-related Macular Degeneration
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedSep 30, 2021
Enrollment StartOct 4, 2021
Primary CompletionNov 7, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 4.8 years ago

Interventions

Resveratrol, Quercetin, Curcumin (RQC)drug

100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID

Curcumindrug

1000 mg curcumin BID